PubMed Health⌕ Search

Biomedical subjects

G Artioli

Publications and source records attributed to G Artioli.

9 recordsLinked to original sources
PubMed2006

Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature.

BACKGROUND: Advanced biliary tract cancers have a poor prognosis. Gemcitabine (G) as a single agent or in combination represents an active treatment option. Systemic chemotherapy in hepatocellular carcinoma represents a palliative treatment. Gemcitabine in combination with Liposomal Doxorubicin (LD) may represent an active treatment option. PATIENTS AND METHODS: Clinical trials for biliary and hepatic carcinoma have been reviewed. RESULTS: We obtained RC (1 pt), RP (4 pts), SD (8 pts) and seven pts had PD (RR 25% and SD 40%). Our chemotherapy regimen was Gemcitabine 1000 mg/m(2) d 1 and 8, Liposomal Doxorubicin 30 mg d 1, q 28. Patients were 21 (17 M), aged 44 to 78 (median 63 yrs). Only in 8 pts we observed G 3-4 haematological toxicity, thrombocytopenia and neutropenia (7 G3, 1 G4).

Adenocarcinoma↗
PubMed2005

Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer.

OBJECTIVE: This phase II study evaluated the efficacy and safety of pegylated liposomal doxorubicin (PLD) 30 to 35 mg/m(2) plus oxaliplatin 70 mg/m(2) every 28 days in women with advanced ovarian cancer that recurred or progressed after a platinum-based regimen. METHODS: 43 women received a median of 6 courses of treatment. RESULTS: Objective response was 54% in the evaluable population and was higher in women with platinum-sensitive (67%) compared with platinum-resistant disease (29%). At a median duration of follow-up of 15.5 months, median overall survival was 15.8 months and time to tumor progression 7.3 months. Most toxicity was no greater than grade 1 or 2. There was no grade 3 or 4 palmar-plantar erythrodysesthesia. After 264 cycles administered, neutropenia was the most common cause of severe toxicity and required one patient to withdraw from the study. No cardiotoxicity was reported. CONCLUSION: PLD plus oxaliplatin is active and well tolerated in women with relapsed advanced ovarian cancer, regardless of platinum sensitivity.

Adult↗
PubMed2001

Ti location in the MFI framework of Ti-Silicalite-1: a neutron powder diffraction study.

The first direct evidence that Ti atoms are not equally distributed in the 12 crystallographically independent T sites of the MFI framework is presented on the basis of neutron diffraction data collected at the HRPD instrument of the ISIS pulsed neutron source. We found strong evidence indicating that T6, T7, and T11 are the most populated sites and weak evidence that Ti may be hosted in T10. Ti occupancy can be excluded for sites T1, T2, T4, T5, T9, and T12. The occupancy of the remaining sites is doubtful. Since defective silicalite has been shown to exhibit the same preferential sites (T6, T7, T11, and T10) for Si vacancies, it may be suggested that the incorporation mechanism of the Ti atoms in the MFI framework occurs via the insertion of titanium in the defective sites. This hypothesis implies that titanium has a mineralizing effect on the MFI framework, and it is supported by independent spectroscopic data on both TS-1 and defective silicalite. The results are discussed in comparison with the known substitution mechanisms in the T-sites of MFI-type structures.

Journal Article↗
PubMed2001

Elderly ovarian cancer: treatment with mitoxantrone-carboplatin.

OBJECTIVE: Data concerning optimal treatment of elderly patients with ovarian cancer are scanty. The management of ovarian cancer in the aged patient is many-sided: the diagnosis can be difficult and delayed, and aggressive surgery is often not attempted because of concomitant morbidity. We tested a combination of carboplatin and mitoxantrone potentially associated with low toxicity in elderly patients with ovarian cancer. METHODS: Eighty-two patients older than 70 years (median age, 75; range, 70-88) with epithelial ovarian cancer were referred to our multicenter group and enrolled into this pilot study. Carboplatin (JM8) was given at the dose of 230 mg/m2 and mitoxantrone at the dose of 9 mg/m2 every 28 days. RESULTS: Dose-limiting toxicity was represented by 4 cases of thrombocytopenia and 1 case of gastrointestinal toxicity. These 5 episodes occurred in 328 assessable cycles, representing a low toxicity profile (3%). Of the 68 assessable patients, 36 (53%) did not respond to chemotherapy (no change + progressive disease), complete response was observed in 15 (22%), and partial remission was observed in 16 (23.5%), accounting for an overall response rate of 45%. CONCLUSION: The carboplatin-mitoxantrone combination, at the dosage tested in this study, appears to be well tolerated by elderly patients with advanced ovarian cancer and is associated with an acceptable response rate. Optimally debulked patients also showed improved survival when compared with patients with more extensive tumor.

Aged↗
PubMed2001

BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling.

Women in general have a 10% risk of developing breast cancer and a 2-3% chance of ovarian cancer in their life-times. Mutations in BRCA-1 and BRCA-2 are present in only a small portion (5-10%) of all breast cancers. Carriers of mutations in these genes have a greater risk of cancer, especially before menopause in the case of BRCA-1 carriers. In addition, their risk of contralateral breast cancer is significantly higher than for the general population (4.2-53% vs. 2%). The grade of contralateral tumours in these patients is more aggressive. BRCA-2 hereditary breast cancer seems more heterogeneous than the BRCA-1 phenotype, and not clearly different from sporadic forms. However, since 20-30% of carriers of BRCA mutations never develop breast or ovarian cancer, there must be other 'risk modifiers'. Survival is better for carriers of hereditary ovarian cancer. Patients with these mutations are referred for genetic counselling, a complex process which includes: an informative dialogue between the proband and the geneticist, drawing up a family history, informed consent, evaluation of risk, genetic testing and possible involvement of healthy family members.

BRCA1 Protein↗
PubMed2000

Neutron powder diffraction study of orthorhombic and monoclinic defective silicalite

The crystal structure of silicalite (SiO2) with a substantial amount of structural hydroxyl groups [Si(1-x)O(2-4x)(OH)4x, with 0.08<x<0.10] has been refined from neutron powder diffraction data measured using the HRPD instrument at the ISIS pulsed neutron source. Powder data were collected on the as-synthesized orthorhombic sample at 298 K, and on the deuterated monoclinic sample at 100 K. Preferential location of Si-atom vacancies was found on four out of 12 independent T sites in the orthorhombic silicalite [Si(6), Si(7), Si(10) and Si(11)], although the H atoms of the substituting hydroxyl groups could not be located because of the low statistical site occupancy on multiple sites. No significant population of D atoms or of Si vacancies was found in the tetrahedral sites of the monoclinic sample. The detected long-range order of adjacent Si atoms in defective orthorhombic [MFI] structures is compatible with a mechanism of Si vacancy clustering and with the model of hydroxyl nests assumed in the literature on the basis of IR spectroscopic evidence. Crystal data: orthorhombic, Pnma, Z = 8, a = 20.0511 (1), b = 19.8757 (1), c = 13.36823 (9) A, V = 5327.62 (5) A3, Dx = 1.798 g cm(-3), Mr = 721.01; monoclinic, P2(1)/n, Z = 4, a = 19.8352 (2), b = 20.0903 (2), c = 13.3588 (1) A, beta = 90.892 (1), V = 5322.78 (6) A3, Dx = 1.799 g cm(-3), Mr = 1442.02.

Journal Article↗